SLC5A2 and ocular melanoma: These include Angiotensin Receptor Neprilysin Inhibitors (ARNI), Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT-2), soluble Guanylate Cyclase Stimulators such as Vericiguat, If channel inhibitors like Ivabradine, selective cardiac myosin activators [25,26] (Omecamtiv Mecarbil, OM), etc. The therapeutic agent’s choice varies with the stage of heart failure.